Precision Medicine in Low‐ and Middle‐Income Countries

Zgheib, Nathalie K.; Patrinos, George P.; Akika, Reem; Mahfouz, Rami

doi:10.1002/cpt.1649

Cited by 13 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An example of such a strategy is the Benefit and Risk Assessment for Off‐label use (BRAvO) framework, described in the Tutorial by van der Zanden and colleagues 9 as a tool to guide age‐appropriate dose selection in children. The development and implementation of individualized treatment regimens for pediatric patients in developing countries is often made even more challenging due to additional complicating factors, such as malnutrition and comedication 10 . Hughes et al .…”

Section: Figurementioning

confidence: 99%

Diversity in Clinical Pharmacology and Therapeutics

Graaf

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Diversity in Clinical Pharmacology and Therapeutics

Graaf

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

“…Precision medicine has not been a field with extensive research, with less information available in areas with high population and ethnic diversity. Deficiencies in certain areas make this task even more challenging, such as inadequate infrastructure, insufficient resources, suboptimal regulations, and scientists not at the forefront of these technologies ( 58 ). With respect to PO in Latin America, although it has gained interest, as demonstrated by LMIC being the area with the most significant average annual growth from 2005 to 2012 in clinical trial participation (33%).…”

Section: Introductionmentioning

confidence: 99%

Integration of artificial intelligence and precision oncology in Latin America

Sussman

García-Robledo

Ordóñez-Reyes

et al. 2022

Front. Med. Technol.

View full text Add to dashboard Cite

Next-generation medicine encompasses different concepts related to healthcare models and technological developments. In Latin America and the Caribbean, healthcare systems are quite different between countries, and cancer control is known to be insufficient and inefficient considering socioeconomically discrepancies. Despite advancements in knowledge about the biology of different oncological diseases, the disease remains a challenge in terms of diagnosis, treatment, and prognosis for clinicians and researchers. With the development of molecular biology, better diagnosis methods, and therapeutic tools in the last years, artificial intelligence (AI) has become important, because it could improve different clinical scenarios: predicting clinically relevant parameters, cancer diagnosis, cancer research, and accelerating the growth of personalized medicine. The incorporation of AI represents an important challenge in terms of diagnosis, treatment, and prognosis for clinicians and researchers in cancer care. Therefore, some studies about AI in Latin America and the Caribbean are being conducted with the aim to improve the performance of AI in those countries. This review introduces AI in cancer care in Latin America and the Caribbean, and the advantages and promising results that it has shown in this socio-demographic context.

show abstract

“…Directing the lens to the Middle East and North Africa region, we are introduced to additional and unique challenges. A perspective paper by Zgheib et al [19] mapped the landscape of precision medicine as well as the gap, challenges, and needs in low- and middle-income countries. The researchers projected the model of “fast-second winner” that recommends pursuing country-specific genome-wide association.…”

Section: Introductionmentioning

confidence: 99%

Stakeholders’ Interest and Attitudes toward Genomic Medicine and Pharmacogenomics Implementation in the United Arab Emirates: A Qualitative Study

Rahma

Elbarazi

Ali

et al. 2021

Public Health Genomics

Self Cite

View full text Add to dashboard Cite

Background and Aim: Mapping the power, interest, and stance of stakeholders is a cornerstone for genomic medicine implementation. In this study, we aimed at mapping the power/interest of various stakeholders in United Arab Emirates (UAE) and exploring their attitudes toward pressing health genomics aspects. The overarching aim of this study is to facilitate the construction of a road map for the full implementation of genomic medicine and pharmacogenomics in the UAE with potential applicability to many healthcare systems around the world. Methods: A qualitative approach using in-depth interview was employed. Heterogeneous stakeholders were identified by experts in the field. The analysis of the data was a hybrid of deductive and inductive approach using NVivo software for coding and analysis. Results: 13 interviews were conducted. Following mapping the Mendelow’s matrix, we categorized the stakeholders in UAE to promoter, latent, defender, and apathetic. Most of the interviewed stakeholders emphasized the clinical demand for genomic medicine in UAE. However, many of them were less inclined to articulate the need for pharmacogenomics at the moment. The majority of stakeholders in UAE were in favor of building infrastructure for better genetic services in the country. Stakeholder from an insurance sector had contradicting stance about the cost-effectiveness of genomic medicine; the majority were concerned with the legal and ethical aspects of genomic medicine and had an opposing stance on direct-to-consumer kits. Conclusions: Implementing the Mendelow’s model will allow the systematic strategy for implementing genomic medicine in UAE. This can be achieved by engaging the key players (promoters and defenders) as well as engaging and satisfying the latent stakeholder.

show abstract

Precision Medicine in Low‐ and Middle‐Income Countries

Cited by 13 publications

References 9 publications

Diversity in Clinical Pharmacology and Therapeutics

Diversity in Clinical Pharmacology and Therapeutics

Integration of artificial intelligence and precision oncology in Latin America

Stakeholders’ Interest and Attitudes toward Genomic Medicine and Pharmacogenomics Implementation in the United Arab Emirates: A Qualitative Study

Contact Info

Product

Resources

About